Life Sciences Tools and Services
Company Overview of Clinipace Worldwide, Inc.
Clinipace Worldwide, Inc. provides digital contract research solutions to pharmaceutical, biotechnology, and medical device companies. It offers clinical research, strategic product development, clinical development, regulatory, GxP/chemistry, manufacturing, and control (CMC)/quality assurance, and post-approval services in various therapeutic areas, such as cardiovascular and metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies). The company also provides biostatistics, clinical monitoring, data management, good clinical practice tra...
3800 Paramount Parkway
Morrisville, NC 27560
Founded in 2003
Key Executives for Clinipace Worldwide, Inc.
Co-Founder, Chief Executive Officer and Director
Co-Founder, President and General Counsel
Chief Executive Officer of European Operations
Compensation as of Fiscal Year 2014.
Clinipace Worldwide, Inc. Key Developments
Clinipace Worldwide Appoints Fred B. Davenport, Jr. to its Board of Directors
Feb 18 15
Clinipace Worldwide announced the addition of Fred B. Davenport, Jr., to its Board of Directors. As an independent director, Fred brings to Clinipace a significant pedigree in scaling global organizations within the CRO industry, having spent 10 years at Pharmaceutical Product Development, Inc.
Roger Morgan Joins Clinipace Worldwide, Inc. as Executive Vice President, Global Medical Affairs
Jun 11 14
Clinipace Worldwide, Inc. announced the addition of Dr. Roger Morgan, MD, FACS, as Executive Vice President, Global Medical Affairs. Dr. Morgan has experience in global medical affairs with both pharmaceutical companies and CROs. While trained as a surgeon/critical care intensivist, he spent much of his industry career focused on cardiovascular research. Dr. Morgan provides oversight and leadership for the global Medical Affairs department, including the cardiometabolic team, medical monitoring, and the pharmacovigilance/safety groups. His responsibilities also include providing senior medical/safety oversight of clinical trials to ensure standard operating procedures, sponsor directives, and patient safety regulatory requirements are followed. In addition, Dr. Morgan will be a resource for the Regulatory and Strategic Development, Business Development, Clinical Operations, and Informatics teams. Prior to Clinipace, Dr. Morgan served as the Medical Director, then Chief Medical Officer at Kowa Research Institute, where he worked on multiple cardiovascular, endocrine, ophthalmologic, and other therapeutic programs, and evaluated multiple preclinical molecules and potential in-licensing candidates in these areas.
Karyopharm Therapeutics Signs Preferred Provider Agreement with Clinipace Worldwide
Apr 10 14
Karyopharm Therapeutics revealed the execution of a preferred provider agreement to manage several clinical programmes, including oncology, wound healing and other diseases in partnership with Clinipace Worldwide. Under the long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions